198 related articles for article (PubMed ID: 26079328)
1. Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.
Vela L; Marzo I
Curr Opin Pharmacol; 2015 Aug; 23():74-81. PubMed ID: 26079328
[TBL] [Abstract][Full Text] [Related]
2. Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects.
Opydo-Chanek M; Gonzalo O; Marzo I
Biochem Pharmacol; 2017 Jul; 136():12-23. PubMed ID: 28288819
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
[TBL] [Abstract][Full Text] [Related]
4. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
5. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.
Hartman ML; Czyz M
Anticancer Agents Med Chem; 2012 Oct; 12(8):966-81. PubMed ID: 22263800
[TBL] [Abstract][Full Text] [Related]
6. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
7. Robust lanthanide-based assays for the detection of anti-apoptotic Bcl-2-family protein antagonists.
Rega MF; Reed JC; Pellecchia M
Bioorg Chem; 2007 Apr; 35(2):113-20. PubMed ID: 16996562
[TBL] [Abstract][Full Text] [Related]
8. The BCL-2 protein family, BH3-mimetics and cancer therapy.
Delbridge AR; Strasser A
Cell Death Differ; 2015 Jul; 22(7):1071-80. PubMed ID: 25952548
[TBL] [Abstract][Full Text] [Related]
9. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
10. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy.
Tomek M; Akiyama T; Dass CR
J Pharm Pharmacol; 2012 Dec; 64(12):1695-702. PubMed ID: 23146031
[TBL] [Abstract][Full Text] [Related]
11. New dimension in therapeutic targeting of BCL-2 family proteins.
Besbes S; Mirshahi M; Pocard M; Billard C
Oncotarget; 2015 May; 6(15):12862-71. PubMed ID: 25970783
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 family members as molecular targets in cancer therapy.
Marzo I; Naval J
Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 family proteins as targets for anticancer drug design.
Huang Z
Oncogene; 2000 Dec; 19(56):6627-31. PubMed ID: 11426648
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic inhibition of BCL-2 and related family members.
Levy MA; Claxton DF
Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
[TBL] [Abstract][Full Text] [Related]
15. Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.
Melo G; Silva CAB; Hague A; Parkinson EK; Rivero ERC
Oral Oncol; 2022 Sep; 132():105979. PubMed ID: 35816876
[TBL] [Abstract][Full Text] [Related]
16. Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.
Karpel-Massler G; Ishida CT; Zhang Y; Halatsch ME; Westhoff MA; Siegelin MD
Expert Opin Drug Discov; 2017 Oct; 12(10):1031-1040. PubMed ID: 28712306
[TBL] [Abstract][Full Text] [Related]
17. Nuclear magnetic resonance study of protein-protein interactions involving apoptosis regulator Diva (Boo) and the BH3 domain of proapoptotic Bcl-2 members.
Santiveri CM; Sborgi L; de Alba E
J Mol Recognit; 2012 Dec; 25(12):665-73. PubMed ID: 23192964
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy.
Richardson A; Kaye SB
Curr Mol Pharmacol; 2008 Nov; 1(3):244-54. PubMed ID: 20021437
[TBL] [Abstract][Full Text] [Related]
19. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.
Sarosiek KA; Letai A
FEBS J; 2016 Oct; 283(19):3523-3533. PubMed ID: 26996748
[TBL] [Abstract][Full Text] [Related]
20. BH3-only proteins: the death-puppeteer's wires.
Ghiotto F; Fais F; Bruno S
Cytometry A; 2010 Jan; 77(1):11-21. PubMed ID: 19899133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
